FY2028 Earnings Forecast for AGIO Issued By Zacks Research

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Zacks Research issued their FY2028 EPS estimates for shares of Agios Pharmaceuticals in a report released on Wednesday, March 4th. Zacks Research analyst Team forecasts that the biopharmaceutical company will earn ($3.61) per share for the year. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share.

Other equities analysts have also recently issued research reports about the company. Truist Financial boosted their price objective on Agios Pharmaceuticals from $32.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, December 24th. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Monday, December 29th. JPMorgan Chase & Co. upped their price target on shares of Agios Pharmaceuticals from $20.00 to $25.00 and gave the stock a “neutral” rating in a report on Tuesday, January 6th. Bank of America lifted their price objective on shares of Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, December 24th. Finally, Citigroup boosted their price objective on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a “buy” rating in a research report on Thursday. Six analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $40.67.

Agios Pharmaceuticals Trading Down 1.8%

Shares of NASDAQ:AGIO opened at $27.68 on Friday. Agios Pharmaceuticals has a 12 month low of $22.24 and a 12 month high of $46.00. The company has a market capitalization of $1.62 billion, a price-to-earnings ratio of -3.89 and a beta of 0.89. The firm’s 50-day moving average is $28.07 and its 200 day moving average is $33.33.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AGIO. Caitong International Asset Management Co. Ltd acquired a new position in Agios Pharmaceuticals in the 4th quarter worth about $183,000. Seven Fleet Capital Management LP purchased a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $864,000. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $25,000. Invesco Ltd. lifted its position in shares of Agios Pharmaceuticals by 12.3% during the 4th quarter. Invesco Ltd. now owns 142,580 shares of the biopharmaceutical company’s stock valued at $3,881,000 after buying an additional 15,604 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in Agios Pharmaceuticals in the 4th quarter valued at $1,253,000.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,932 shares of the business’s stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $79,427.88. Following the sale, the insider owned 29,190 shares of the company’s stock, valued at approximately $790,757.10. The trade was a 9.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Sarah Gheuens sold 2,932 shares of the firm’s stock in a transaction on Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total transaction of $79,427.88. Following the completion of the transaction, the insider directly owned 64,795 shares of the company’s stock, valued at approximately $1,755,296.55. This represents a 4.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 33,303 shares of company stock valued at $901,977. Corporate insiders own 4.30% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.